Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

NCT07165132 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT07165132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07165132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.
Lead sponsor
RayzeBio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 3, 2025
Completion date
April 30, 2033
Enrollment
104 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, carcinoid tumor, gastroenteropancreatic neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumor disease, gep-net, neuroendocrine tumors, pancreatic net, solid tumor, somatostatin receptor